|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Human BMF / Bcl2 modifying factor protein (Catalog#13639-H07E)|
|0.2 μm filtered solution in PBS|
|Produced in rabbits immunized with purified, recombinant Human BMF / Bcl2 modifying factor (rh BMF / Bcl2 modifying factor; Catalog#13639-H07E; Q96LC9-1; Met1-Arg184). BMF / Bcl2 modifying factor specific IgG was purified by Human BMF / Bcl2 modifying factor affinity chromatography.|
|Human BMF / Bcl2 modifying factor|
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human BMF / Bcl2 modifying factor. The detection limit for Human BMF / Bcl2 modifying factor is < 0.039 ng/well.
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
BMF(Bcl2 modifying factor) belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. BMF contains a single BCL2 homology domain 3 (BH3), and has been shown to bind BCL2 proteins and function as an apoptotic activator. BMF is found to be sequestered to myosin V motors by its association with dynein light chain 2, which may be important for sensing intracellular damage and triggering apoptosis. Alternatively spliced transcript variants encoding different isoforms have been identified.